secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2022-05-24T23:59:59+00:00
Accession:  0001437749-22-013326
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Diffusion Pharmaceuticals appoints Raven Jaeger as Chief Regulatory Officer
---------------------------------------------------------------------------

- Raven Jaeger, former SVP Regulatory Affairs at BridgeBio, named Chief Regulatory Officer effective May 18, 2022.
- She brings 20 years regulatory experience, including leading team to first FDA approval at BridgeBio.
- Compensation: $400k base salary, 35% target bonus, $60k sign-on bonus, 8,000 stock options vesting over 36 months.
- She will oversee regulatory strategy for lead candidate TSC (trans sodium crocetinate) for hypoxic solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774922013326/0001437749-22-013326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774922013326/dffn20220523_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-013326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer